NBTXR3 | Nano Publications

2018 – ESMO – Phase II/III NBTXR3 in STS

Abstracts, Donnée clinique de NBTXR3, STM

NBTXR3 is a first-in-class Hafnium-Oxide nanoparticle intratumorally (IT) injected. When activated by radiotherapy (RT), it allows for a higher energy deposit than RT alone, yielding an increased tumoral cell death. A phase I study in soft tissue sarcoma (STS) showed that a single NBTXR3 IT injection at 10% of the baseline tumor volume with preoperative RT was technically feasible with manageable toxicity and clinical activity was observed. […]

Continuer la lecture…

2018 – ASCO – NBTXR3 generates an anti-tumor immune response

Abstracts, Abstracts, In Vivo

The enclosed abstract was presented at the 13th Journées cancéropole Grand Sud-Ouest at Poitiers. The abstract Hafnium oxide nanoparticles as an emergent promising treatment for solid tumors describes how hafnium oxide nanoparticles were designed at the nanoscale in the form of crystalline 50nm-particles to efficiently absorb ionizing radiation and increase the radiation dose deposited – “hot spots” of energy deposit – from within the tumor cells for efficient cell killing. […]

Continuer la lecture…

2018 – ASTRO 2018 – NBTXR3 in elderly HNSCC

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

As the incidence of head and neck squamous cell carcinoma (HNSCC) increases with age, elderly patients represent 25% of the affected population with an expected increase in the next 20 years. Being more vulnerable to treatment-induced toxicities, the elderly cannot be treated like younger patients, hence requiring innovative therapies. […]

Continuer la lecture…

2018 – ASTRO 2018 – Phase III NBTXR3 in Soft Tissue Sarcoma

Abstracts, Donnée clinique de NBTXR3, STM

A subset of soft tissue sarcoma (STS) patients achieve significant therapeutic benefit from preoperative radiotherapy (RT). Yet, this treatment paradigm may be associated with limited efficacy and increased toxicity, highlighting the necessity of novel multimodal therapies aimed at local control with few adverse events (AEs). NBTXR3 is a first-in-class Hafnium-Oxide nanoparticle. […]

Continuer la lecture…

2018-ASTRO 2018- NBTXR3 in liver cancers

Abstracts, Donnée clinique de NBTXR3, Foie

Radiation oncology technological development is principally focused in improving the precision of radiotherapy (RT) and reducing unwanted irradiation to normal tissues. There is an unmet medical need into ameliorating the energy dose deposit within tumor cells without increasing the dose received by surrounding healthy tissues. […]

Continuer la lecture…

2018 – ESMO – NBTXR3 in HCC and Liver Metastasis

Abstracts, Donnée clinique de NBTXR3, Foie, Tête & Cou

For patients (pts) with hepatocellular carcinoma (HCC) or liver metastasis (liver mets), stereotactic body radiation therapy (SBRT) is a well-tolerated option. Yet, the risk of injury to normal tissues limits the ability to efficiently sterilize tumor cells. Thus, hafnium oxide nanoparticles, NBXTR3, were developed, which increase the interaction of radiotherapy energy dose deposition within tumor cells when activated by an ionizing energy source like SBRT. […]

Continuer la lecture…

2018 – ASCO – NBTXR3 in the treatment of liver cancer: a phase I/II trial

Abstracts, Donnée clinique de NBTXR3, Foie

With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]

Continuer la lecture…

2018 – ESMO 2018 – NBTXR3 in elderly HNSCC

Abstracts, Donnée clinique de NBTXR3, Foie

Elderly patients (pts) with head and neck squamous cell carcinoma (HNSCC) represent 25% of the affected population. They are not always eligible to the same treatment of younger pts, thus require new therapies. NBTXR3, injectable hafnium oxide nanoparticles activated by radiotherapy (RT), was developed to increase the local deposit of energy within the tumor. […]

Continuer la lecture…

2018 – ESTRO – Hafnium Oxide Nanoparticles and Radiotherapy: A Promising New Treatment Strategy

Abstracts, Donnée clinique de NBTXR3, Foie, Rectum, STM, Tête & Cou

Continuer la lecture…

2018 – ESMO WGI – NBTXR3 in HCC and Liver Mets

Abstracts, Donnée clinique de NBTXR3, Foie

Management of hepatocellular carcinoma (HCC) and liver metastasis (mets) requires complementary expertise of multiple specialties. Treatment decisions are increasingly complex and physicians must face a wide range of underlying liver dysfunctions and concomitant malignancies. Among available treatments, stereotactic body radiation therapy (SBRT) is well-tolerated. […]

Continuer la lecture…